It’s been a really good year for Exelixis (NASDAQ: EXEL). The biotech’s share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But it’s been a really great year for Immunogen (NASDAQ: IMGN): The stock has soared nearly 270%.
The past is the past, though. Which of these cancer-focused biotech stocks is the better choice for investors now? Here’s how Exelixis and Immunogen compare.
Image source: Getty Images.